Rifampicin is named as a drug or biological intervention in 8 clinical trials in our China and India trial registers, 7 of which are recruiting. Lead sponsors include National Institute of Allergy and Infectious Diseases (NIAID) (2), Indian Council of Medical Research (1) and Qilu Pharmaceutical Co., Ltd. (1). Registered phases: Phase 2, Phase 3, Phase 1, Phase 4 and Not applicable. Conditions studied include Tuberculous Meningitis; Pulmonary Tuberculosis; Refractory or Relapsed Solid Tumors.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Tuberculous Meningitis | 2 |
| Pulmonary Tuberculosis | 2 |
| Refractory or Relapsed Solid Tumors | 1 |
| Mycobacterium Avium Complex Pulmonary Disease | 1 |
| Periprosthetic Joint Infection | 1 |
| Clinical Pharmacology | 1 |
| Lead sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Indian Council of Medical Research | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
| Shenzhen Third People's Hospital | 1 |
| Bin Cao | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Register | Rifampicin trials |
|---|---|
| Clinical trials in China | 5 |
| Clinical trials in India | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rifampicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rifampicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.